Business
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures All SUNRISE-FA participants achieved meaningful increases in frataxin expression at 3-months post treatment; 115% average cardiac frataxin expression increase in high dose cohort, demonstrating dose response Frataxin expression and LVMI improvement excee
About this update from Lexeo Therapeutics, Inc.
[{"type":"image","alt":"Lexeo Therapeutics","displaySize":"","headline":null,"caption":"Lexeo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZNNLd9kZ10lMRyd7r.aoKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac","width":300,"height":116}},"lazy":false},{"type":"text","content":"Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner","length":132,"tagName":"p"},{"type":"text","content":"Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures ","length":112,"tagName":"p"},{"type":"text","content":"All SUNRISE-FA participants achieved meaningful increases in frataxin expression at 3-months post treatment; 115% average cardiac frataxin expression increase in high dose cohort, demonstrating dose response","length":207,"tagName":"p"},{"type":"text","content":"Frataxin expression and LVMI improvement exceed co-primary target thresholds for planned registrational study","length":109,"tagName":"p"},{"type":"text","content":"LX2006 generally well tolerated with no signs of complement activation or other immunogenicity to date","length":102,"tagName":"p"},{"type":"text","content":"Company to host webcast today at 8:00 AM ET","length":43,"tagName":"p"},{"type":"text","content":"NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. In both the Lexeo-sponsored SUNRISE-FA Phase 1/2 clinical trial (NCT05445323) and the Weill Cornell Medicine investigator-initiated Phase 1A trial (NCT05302271), treatment with LX2006 was associated with clinically significant improvements in cardiac biomarkers and functional measures, and increased frataxin protein expression was observed in all participants with cardiac biopsies.","length":714,"tagName":"p"},{"type":"text","content":"“These data provide strong evid...